Phi-Medics

Executive Summary

Phi-Medics is a UK-based consulting firm specializing in clinical research, development, and medical affairs services for the pharmaceutical industry, with a strong focus on oncology and hematology. Founded in 2016, the company provides project-based and interim management solutions, leveraging deep expertise to help clients navigate drug development and commercialization. As a strategic partner, Phi-Medics addresses the complexities of bringing new therapies to market, offering tailored support from early-stage development through regulatory approval and market access. The firm's niche in oncology and hematology positions it well in high-growth therapeutic areas, though its service-based model means revenue is tied to client engagements rather than proprietary assets. With a lean operation and a focus on specialized consulting, Phi-Medics has the potential to scale by attracting larger pharma clients and expanding its service offerings. However, its growth trajectory depends on maintaining client relationships and winning new contracts in a competitive landscape.

Upcoming Catalysts (preview)

• Q3 2026Major Pharma Contract Win40% success
• Q4 2026Expansion into New Therapeutic Area30% success
• TBDStrategic Partnership or Acquisition25% success